Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Large Growth in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 221,900 shares, a growth of 14.3% from the March 15th total of 194,200 shares. Based on an average daily volume of 224,000 shares, the short-interest ratio is currently 1.0 days. Currently, 1.9% of the shares of the company are sold short.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock traded down $0.07 on Tuesday, hitting $0.66. The company had a trading volume of 37,664 shares, compared to its average volume of 207,249. The business has a 50-day simple moving average of $0.73 and a 200-day simple moving average of $0.66. The company has a market cap of $7.30 million, a PE ratio of -0.31 and a beta of 0.36. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.89.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.14. During the same quarter in the prior year, the firm earned ($0.72) earnings per share. On average, equities research analysts predict that Chemomab Therapeutics will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMMB. Two Sigma Investments LP acquired a new stake in Chemomab Therapeutics during the first quarter valued at approximately $48,000. Envestnet Asset Management Inc. acquired a new stake in Chemomab Therapeutics during the first quarter valued at approximately $52,000. Citadel Advisors LLC acquired a new stake in Chemomab Therapeutics during the third quarter valued at approximately $53,000. Renaissance Technologies LLC acquired a new stake in Chemomab Therapeutics during the first quarter valued at approximately $134,000. Finally, Boothbay Fund Management LLC lifted its position in shares of Chemomab Therapeutics by 38.1% in the 4th quarter. Boothbay Fund Management LLC now owns 51,608 shares of the company’s stock valued at $165,000 after acquiring an additional 14,237 shares in the last quarter. 46.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on CMMB. Roth Capital reissued a “buy” rating on shares of Chemomab Therapeutics in a research note on Tuesday, December 19th. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price target on shares of Chemomab Therapeutics in a research note on Tuesday, December 19th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).